Clinical Evidence is one of the world's most authoritative medical resources for informing treatment decisions and improving patient care.
Latest updated reviews
- Kidney stones (updated)
- Atrial fibrillation (chronic) (updated)
- Generalised anxiety disorder (updated)
- Depression in children and adolescents (updated)
- Carpal tunnel syndrome (updated)
- Influenza (updated)
- Insomnia (primary) in older people (updated)
- Opioid dependence (updated)
- Neonatal jaundice (updated)
- Summary of all updates
Editorial
Since 2004, Clinical Evidence has undergone multiple changes to enhance the accessibility of the content and maximise the transparency and usefulness of the evidence presented. Key initiatives include the creation of a key points section and addition of a GRADE system. Now, as Karen Pettersen highlights in her Editorial, we are pleased to announce the launch of a new tabulated format for presentation of the data in half of our reviews (please see our review on heart failure as an example). We hope you find the new data display helpful in understanding the benefits and harms of interventions and, most importantly, in making better decisions, together with patients.
New website 2012
We are pleased to announce that from January 2012 Clinical Evidence will feature a new design and additional tools to help you teach, learn and practice evidence-based medicine. Click here for a preview
Drug safety alerts
- FDA issues drug safety alert on the possible increased risk of QT prolongation associated with ondansetron, and warning to avoid use in patients with congenital long QT syndrome.
(15 September 2011) - FDA issues drug safety alert on the increased risk of being diagnosed with a more serious form of prostate cancer (high-grade prostate cancer) associated with 5-alpha reductase inhibitors (finasteride or dutasteride) however this risk appears to be low.
(09 June 2011) - EMA issues drug safety alert on the increased risk of venous thromboembolism (VTE) associated with drospirenone-containing combined oral contraceptives (COCs) compared with levonorgestrel-containing COCs. The risk with drospirenone-containing COCs may be similar to that with desogestrel or gestodene-containing COCs. The alert states that the risk of VTE with any COC (including those containing drosperinone) is very small.
(26 May 2011)
Consultancy reviews
Palliative care
Our latest review synthesises the evidence for key elements of palliative care: symptom control; communication and transition management and provides practical toolkits.
Smoking cessation
We present a new review on an evidence-based approach to Smoking cessation.
Managing HIV infection
View our systematic reviews on the challenges of managing HIV/AIDS in resource-poor settings.
January 28, 2012
News Feeds & Email Alerts
Clinical Evidence Userguide
